Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
RNXT
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
NASDAQ
Unprofitable
EPS improving
Unprofitable
EPS improving
0.01 ( 0.83%)
Pre-market 1.22$0.00 (0.00%)
Relative Strenght
75
Volume Buzz
-74%
Earning Acce
No
Dist 52w H.
28%Earnings Growth
YoY
Current
Estimates
Q2.23
N/A
-0.22
vs -0.29
Q3.23
N/A
-0.27
vs -0.24
Q4.23
N/A
-0.31
vs -0.23
Q1.24
N/A
-0.17
vs -0.36
Q2.24
N/A
-0.10
vs -0.22
Q3.24
N/A
-0.10
vs -0.27
Q4.24
N/A
-0.12
vs -0.31
Q1.25
N/A
-0.08
vs -0.17
Q2.25
N/A
-0.09
vs -0.10
Q3.25
N/A
-0.08
vs -0.10
Sales Growth
YoY
Current
Estimates
Q2.23
NA
NA vs NA
Q3.23
NA
NA vs NA
Q4.23
NA
NA vs NA
Q1.24
NA
NA vs NA
Q2.24
NA
NA vs NA
Q3.24
NA
NA vs NA
Q4.24
NA
43K vs NA
Q1.25
NA
197K vs NA
Q2.25
NA
329.6K vs NA
Q3.25
NA
503.9K vs NA
Return on Equity
QoQ
Q2.23
-196%
-1.96
vs -1.00
Q3.23
-23683%
-236.83
vs -1.96
Q4.23
+108%
1.08
vs -236.83
Q1.24
-61%
-0.61
vs 1.08
Q2.24
-26%
-0.26
vs -0.61
Q3.24
-35%
-0.35
vs -0.26
Q4.24
-64%
-0.64
vs -0.35
Q1.25
-18%
-0.18
vs -0.64
Institutionnal Ownership
QoQ
Q2.23
9
9
vs 12
-25%
Q3.23
14
14
vs 9
56%
Q4.23
11
11
vs 14
-21%
Q1.24
9
9
vs 11
-18%
Q2.24
16
16
vs 9
78%
Q3.24
13
13
vs 16
-19%
Q4.24
18
18
vs 13
38%
Q1.25
26
26
vs 18
44%
businesswire.com
8 hours ago
businesswire.com
16 hours ago
zacks.com
20 hours ago
seekingalpha.com
21 hours ago
Quote Panel
Key Metrics
Relative Strength
RNXT
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
2656%2026-Revenue
-313%2026-EPS
205%2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
Ascendiant
initialisePrevious: Not converted
2024-06-17
Now: Buy
Maxim Group
upgradePrevious: Not converted
2024-02-29
Now: Buy